Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMINI-Hepatobiliary
NCT05775159Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of volrustomig, rilvegostomig in hepatocellular carcinoma (HCC), biliary tract cancer (BTC), sponsored by AstraZeneca. Started Apr 2023; status: active, not recruiting.
02
Drugs
volrustomigrilvegostomig
03
Conditions
hepatocellular carcinoma (HCC)biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05775159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05775159.